ATAnchal Trivedi

Anchal Trivedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anchal Trivedi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Apoptosis Induction, Disruption of Cytoskeleton Remodeling and EMT Inhibition as Major Mechanism(s) Underlying the Pleiotropic Action of Withania somnifera in Breast Cancer

    by Aditi Srivastava, Tanveer Ahamad, Aqib Sarfraz, Sahabjada Siddiqui, Feroz Khan, Anchal Trivedi, Mohd. Faheem Khan, Aparna Misra, Hari Shankar, Mohsin Ali Khan, et al.

    The role of actin and its binding proteins has been discovered in cytoskeleton remodeling as well as in Epithelial‐Mesenchymal Transition (EMT) of metastatic cells and apoptosis. Even minor changes in the biomolecular structure of actin and its ABPs (by binding of ligands) can lead to drastic changes in the cytoskeleton with far reaching effects per se. Agents targeting actin can, thus, be viewed as potential anti‐metastatic agents. The effect of Withania somnifera (L.) Dunal (WS) on the cytoskeleton has remained relatively unexplored. The present study highlights the interaction between 20 WS phytoconstituents and 10 selected cytoskeletal proteins in silico with a view to validate and analyze the perturbation in growth and differentiation of breast cancer cells in vitro. Pharmacokinetic analyses revealed that the majority of WS phytoconstituents exhibited no violations of Lipinski's rule‐of‐five parameters. Withanolides A, B, D, M and O displayed the greatest binding affinity particularly for coronin1A, vimentin, gelsolin, ezrin and F‐actin. MD simulations of 100 ns revealed maximum stable interaction(s) between Coronin‐Viscosalactone B (VISCB) and Vimentin‐Withanolide E (WITHE). The prepared methanolic extract of WS stem (WSME), characterized using LC–MS, revealed the presence of Withaferin A (WFA). Both WSME and WFA exhibited potent cytotoxicity against breast cancer MDA‐MB‐231 cells. WSME increased ROS levels, arrested the cell cycle in S and G2‐M phases, decreased the expression of mesenchymal markers, namely, vimentin, N‐cadherin and increased levels of the epithelial marker E‐cadherin in treated MDA‐MB‐231 cells. These findings suggest that VISCB, WITHE, and WFA have the potential to emerge as potential antimetastatic agents against breast cancer in the future.


  • Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines

    by Esha Sarkar, Aparna Misra, Abbas Ali Mahdi, Anchal Trivedi, Afreen Khan

    Chemoresistance is one of the biggest hurdles while treating cancer clinically. Due to its heterogeneous nature, complications of the chemoresistance mechanisms of breast cancer cannot be completely elucidated. Existing mechanisms of main-line drug treatment can slow down the process of malignancy with part and parcel called drug resistance. The combinatorial effect of several chemotherapeutic drugs, targeting different pathways at the same time, can work efficiently, yet the toxicity and drug-drug interaction remain intact. To overcome this hurdle, a number of strategies have been discovered, such as novel agents, drug carriers, and combination treatment, etc., which target mediated drug delivery systems; nanomedicine and the use of phytocompounds can transfer the drug particularly to the cancerous cells with minimal side effects to the neighboring healthy cells. The cell cycle checkpoint proteins and genes induced to the deranged cells can inhibit the resistance mechanism towards the drug. Modification of cell signaling pathways can also help to treat breast cancer chemoresistance mechanisms in the long run. This article reviews the execution and onset of chemoresistance in various cancers and discusses potential therapeutic approaches to deal with the resistance mechanism. This review summarizes the possible mechanisms and signaling pathways causing chemoresistance in breast cancer cell lines and discusses alternative therapy to overcome this issue under pre-clinical and clinical infrastructure.


  • Virtual screening of phytoconstituents from miracle herbnigella sativatargeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment

    by Sahabjada Siddiqui, Shivbrat Upadhyay, Rumana Ahmad, Anamika Gupta, Aditi Srivastava, Anchal Trivedi, Ishrat Husain, Bilal Ahmad, Maqusood Ahamed, Mohsin Ali Khan

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel etiological agent of coronavirus disease 2019 (COVID-19). Nigella sativa, commonly known as black seed or black cumin, has been a historical and traditional plant since thousands of years. Based on their therapeutic efficacy, the chief components of terpenoids and flavonoids were selected from N. sativa seeds and seed oil. This study was designed to check the antiviral efficacy of N. sativa main phytoconstituents against five potential targets of SARS-CoV-2 using in silico structure-based virtual screening approach. Out of twenty five phytocomponents, ten components showed best binding affinity against two viral proteins viz. N-terminal RNA binding domain (NRBD; PDB ID: 6M3M) of nucleocapsid protein and papain-like protease (PL-PRO; PDB ID: 6W9C) of SARS-CoV-2 using AutoDock 4.2.6, AutoDock Vina and iGEMDOCK. PASS analyses of all ten phytocomponents using Lipinski’s Rule of five showed promising results. Further, druglikeness and toxicity assessment using OSIRIS Data Warrior v5.2.1 software exhibited the feasibility of phytocomponents as drug candidates with no predicted toxicity. Molecular dynamics simulation study of NRBD of SARS-CoV-2 nucleocapsid protein-alpha-spinasterol complex and PL-PRO-cycloeucalenol complex displayed strong stability at 300 K. Both these complexes exhibited constant root mean square deviation (RMSDs) of protein side chains and Cα atoms throughout the simulation run time. Interestingly, PL-PRO and NRBD are key proteins in viral replication, host cell immune evasion and viral assembly. Thus, NRBD and PL-PRO have the potential to serve as therapeutic targets for N. sativa phytoconstituents in drug discovery process against COVID-19. Graphical Abstract Communicated by Ramaswamy H. Sarma